Lenalidomide and dexamethasone in treatment of patients with
relapsed and refractory multiple myeloma - analysis of data
from the Czech Myeloma Group Registry of Monoclonal
Gammopathies

J 2019

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

MAISNAR, V., Z. STEFANIKOVA, I. SPICKA, Luděk POUR, J. MINARIK et. al.

Základní údaje

Originální název

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Autoři

MAISNAR, V. (203 Česká republika, garant), Z. STEFANIKOVA (703 Slovensko), I. SPICKA (203 Česká republika), Luděk POUR (203 Česká republika, domácí), J. MINARIK (203 Česká republika), M. FLOCHOVA (203 Česká republika), J. RADOCHA (203 Česká republika), E. GREGORA (203 Česká republika), N. STECOVA (703 Slovensko), T. JELINEK (203 Česká republika), A. JUNGOVA (203 Česká republika), E. KRALIKOVA (703 Slovensko), Lucie BROŽOVÁ (203 Česká republika, domácí) a R. HAJEK (203 Česká republika)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2019, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.721

Kód RIV

RIV/00216224:14110/19:00112506

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2018_180824N644

UT WoS

000491237700020

Klíčová slova anglicky

lenalidomide; dexamethasone; multiple myeloma; relapse; refractory; cytogenetic aberrations

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 13:16, Mgr. Tereza Miškechová

Anotace

V originále

Lenalidomide (LEN) is an immunomodulator with clinical activity against myeloma cells. Based on the pivotal phase 3 trials MM-009 and MM-010, the combination of lenalidomide and dexamethasone(DEX) was approved for patients with multiple myeloma who received at least one prior therapy. Here, we evaluated LEN/DEX therapy in whole population and subsequently in selected sub-groups of patients with relapsed/refractory multiple myeloma followed in the Monoclonal Gammopathy Registry of the Czech Myeloma Group. 858 patients were treated with LEN/DEX in Czech Republic and Slovakia until end of 2017. The analyzed sub-groups were defined as patients with high-risk cytogenetic aberrations and patients with relapsed and refractory MM. The ORR (response better than PR) in whole group of patients was 46.3% for all lines of therapy, 26.4% for high-risk group and 32.1% for relapsed and refractory group. Overall survivals (OS) in the same sets were as follows: 25.6, 15.7 and 18.5 months respectively, progression free survival (PFS) was 11.2, 6.4 and 9.0 months, respectively. The most common adverse events were hematologic and infectious. In conclusion, we found our results correlated with those in other studies in terms of OS, PFS and also of treatment toxicity.

Citovat

MAISNAR, V., Z. STEFANIKOVA, I. SPICKA, Luděk POUR, J. MINARIK, M. FLOCHOVA, J. RADOCHA, E. GREGORA, N. STECOVA, T. JELINEK, A. JUNGOVA, E. KRALIKOVA, Lucie BROŽOVÁ a R. HAJEK. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma. Bratislava: Slovenská akademie vied, 2019, roč. 66, č. 3, s. 499-505. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2018_180824N644.

@article{1605477,
   author = {Maisnar, V. and Stefanikova, Z. and Spicka, I. and Pour, Luděk and Minarik, J. and Flochova, M. and Radocha, J. and Gregora, E. and Stecova, N. and Jelinek, T. and Jungova, A. and Kralikova, E. and Brožová, Lucie and Hajek, R.},
   article_location = {Bratislava},
   article_number = {3},
   doi = {http://dx.doi.org/10.4149/neo_2018_180824N644},
   keywords = {lenalidomide; dexamethasone; multiple myeloma; relapse; refractory; cytogenetic aberrations},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies},
   url = {http://dx.doi.org/10.4149/neo_2018_180824N644},
   volume = {66},
   year = {2019}
}

TY  - JOUR
ID  - 1605477
AU  - Maisnar, V. - Stefanikova, Z. - Spicka, I. - Pour, Luděk - Minarik, J. - Flochova, M. - Radocha, J. - Gregora, E. - Stecova, N. - Jelinek, T. - Jungova, A. - Kralikova, E. - Brožová, Lucie - Hajek, R.
PY  - 2019
TI  - Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
JF  - Neoplasma
VL  - 66
IS  - 3
SP  - 499-505
EP  - 499-505
PB  - Slovenská akademie vied
SN  - 00282685
KW  - lenalidomide
KW  - dexamethasone
KW  - multiple myeloma
KW  - relapse
KW  - refractory
KW  - cytogenetic aberrations
UR  - http://dx.doi.org/10.4149/neo_2018_180824N644
L2  - http://dx.doi.org/10.4149/neo_2018_180824N644
N2  - Lenalidomide (LEN) is an immunomodulator with clinical activity against myeloma cells. Based on the pivotal phase 3 trials MM-009 and MM-010, the combination of lenalidomide and dexamethasone(DEX) was approved for patients with multiple myeloma who received at least one prior therapy. Here, we evaluated LEN/DEX therapy in whole population and subsequently in selected sub-groups of patients with relapsed/refractory multiple myeloma followed in the Monoclonal Gammopathy Registry of the Czech Myeloma Group. 858 patients were treated with LEN/DEX in Czech Republic and Slovakia until end of 2017. The analyzed sub-groups were defined as patients with high-risk cytogenetic aberrations and patients with relapsed and refractory MM. The ORR (response better than PR) in whole group of patients was 46.3% for all lines of therapy, 26.4% for high-risk group and 32.1% for relapsed and refractory group. Overall survivals (OS) in the same sets were as follows: 25.6, 15.7 and 18.5 months respectively, progression free survival (PFS) was 11.2, 6.4 and 9.0 months, respectively. The most common adverse events were hematologic and infectious. In conclusion, we found our results correlated with those in other studies in terms of OS, PFS and also of treatment toxicity.
ER  -

MAISNAR, V., Z. STEFANIKOVA, I. SPICKA, Luděk POUR, J. MINARIK, M. FLOCHOVA, J. RADOCHA, E. GREGORA, N. STECOVA, T. JELINEK, A. JUNGOVA, E. KRALIKOVA, Lucie BROŽOVÁ a R. HAJEK. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2019, roč.~66, č.~3, s.~499-505. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2018\_{}180824N644.

Podrobný výpis o publikaci